샘플 요청 목록

 카트 문의
시장보고서
상품코드
1869755

세계의 신경중재 기기 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 최종 용도별, 지역별 부문 예측(2025-2033년)

Neurointerventional Devices Market Size, Share & Trends Analysis Report By Product (Diagnostic Devices, Therapeutic Devices), By Indication (Acute Ischemic Stroke (AIS), Intracranial Aneurysm), By End Use, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 300 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경중재 기기 시장 요약

세계의 신경중재 기기 시장 규모는 2024년에 29억 5,000만 달러로 추정되었으며, 2033년까지 49억 6,000만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 연평균 복합 성장률(CAGR) 5.9%로 성장할 전망입니다. 이 시장의 주요 성장 요인은 뇌졸중, 뇌동맥류, 혈관 기형 및 기타 신경혈관 질환의 유병률 상승 외에도 이러한 질병에 걸리기 쉬운 노인 인구의 급속한 증가에 있습니다.

개복 수술에 비해 회복이 빠르고 합병증이 적은 저침습 수술에 대한 수요 증가가 시장 성장을 더욱 가속화하고 있습니다. 뇌졸중, 동맥류, 기타 신경혈관 질환 등 신경질환의 발생률 상승은 장애 경감, 생존율 향상, 환자 결과 개선을 기대할 수 있는 효과적인 저침습 치료에 대한 수요를 높이기 때문에 신경중재 기기 시장의 주요 촉진요인이 됩니다. 세계신경학연합(WFN)에 따르면, 신경질환의 유병률은 조산아, 신생아, 소아, 청소년기, 성인, 그리고 나이에 따른 복합 질환이나 허약화를 경험하는 경우가 많은 노인 등 연령층에 따라 다릅니다. 2024년 '세계의 질병 부담' 연구는 세계 인구의 43%가 신경 질환의 영향을 받고 있는 것으로 추정되고 있으며, 신경중재 기기 및 치료법에 대한 세계적인 수요의 크기가 부각되고 있습니다.

차세대 스텐트 리트리버, 플로우 다이버터, 고급 영상 진단 솔루션 등의 기술 진보가 치료 성과를 향상시키고 있습니다. 신흥 시장에서 규제당국의 승인 촉진, 상환 정책의 개선, 의료 인프라의 확충이 신경중재 기기의 보급을 뒷받침하고 있습니다. 예를 들어 2024년 4월, Neurology 전문지는 뇌질환증례 수가 2050년까지 세계에서 49억 건에 달한다는 예측을 게재했으며, 이는 2021년 대비 22% 증가를 보이고 있습니다. 전 연령층에서의 뇌질환의 장애조정 생명년(DALYs)율도 2021년의 10만명당 5,139 DALYs에서 2050년에는 10만명당 5,666 DALYs로 세계적으로 10%의 대폭적인 상승이 전망되고 있습니다. 두통, 알츠하이머 병, 우울증 및 불안 장애, 뇌졸중이 이 유병률과 질병 부담의 예상되는 급증의 주요 요인으로 확인되었습니다.

뇌졸중, 특히 허혈성 뇌졸중의 발생률 상승은 효율적이고 침습성이 낮은 혈전 제거 절차 수요를 증가시킴으로써 신경중재 기기 시장을 견인하고 있습니다. 예를 들어, 2024년 CDC 데이터(아래 표 참조)는 미국에서 연간 79만 5천명 이상이 뇌졸중을 일으키고 있으며 고급 신경중재 치료법의 필요성이 높아지고 있음을 보여줍니다. WHO의 추계에서는 세계의 뇌졸중 연간 발생수는 약 1,500만명으로, 그 약 87%가 허혈성 뇌졸중입니다.

세계 뇌졸중 메커니즘(WSO) 2022년 보고서에 따르면, 아래 표는 허혈성 뇌졸중의 발생률과 유병률을 보여줍니다.

「Journal of Experimental Stroke & Translational Medicine」에 의하면, 출혈성 뇌졸중은 증례의 약 10-15%를 차지하고, 혈관의 파열에 의해 뇌 조직내(뇌내 출혈) 또는 뇌 주위의 공간(거미막밑 출혈)에 출혈이 생기는 것으로 발병합니다.

동맥 정맥 기형(AVM)은 신경중재 장치 시장의 성장을 견인하는 중요한 요소입니다. 이러한 복잡한 혈관 이상은 정밀하고 저침습 치료 방법이 필요하기 때문입니다. 첨단 영상 진단 기술에 의한 AVM의 검출율 향상과 개두 수술보다 혈관내 치료가 선호되는 경향이 강해지고 있는 것이, 색전 시스템, 카테터, 코일 등의 전문적인 신경중재 기기 수요를 뒷받침하고 있습니다. 의료 종사자의 출혈성 합병증 예방을 위한 조기 개입에 대한 인식 증가는 AVM 관리를 위한 고급 신경중재 솔루션의 도입을 더욱 가속화하고 있습니다. 미국 국립생물공학정보센터(NCBI)가 발표한 조사에 따르면 동맥정맥기형(AVM)의 약 15%는 임상증상이 나타날 때까지 무증상인 경우가 많다고 합니다. AVM의 41%에서 79%는 두개내 출혈과 함께 존재합니다. 이들은 뇌동맥류에 이어 두개내 출혈의 두 번째 주요 원인이며, 전혀 막하 출혈의 약 10%를 차지하고 있습니다.

고령화 사회의 진전은 신경중재 기기 시장을 견인하고 있습니다. 노인들은 뇌졸중, 동맥류, 노화성 뇌혈관질환 등 신경혈관 질환을 일으키기 쉬운 경향이 있기 때문입니다. 이 인구 역학의 변화로 인해 저 침습 치료법과 고급 신경혈관 장치에 대한 수요가 높아지고 있습니다. 예를 들어, 2024년 6월에 뇌동맥류 재단이 발표한 데이터에 의하면, 미국에서는 추정 680만명(약 50명에 1명)이 미파열 뇌동맥류를 가지고 있어 연간 파열률은 10만명당 8-10건으로 보고되고 있습니다. 매년 약 30,000명의 미국인이 뇌동맥류 파열을 경험하고 있으며, 이는 평균 18분마다 발생합니다. 세계적으로 보면, 뇌동맥류는 연간 약 50만명의 사망 원인이 되고 있으며, 그 절반은 50세 미만입니다. 대부분의 동맥류는 40세 이후에 발생하며, 35세에서 60세가 가장 많으며 소아에서도 발생할 수 있습니다. 뇌동맥류는 남성보다 여성에게 더 많이 나타나고(3:2 비율), 55세 이상의 여성은 남성에 비해 파열 위험이 약 1.5배 높습니다.

자주 묻는 질문

  • 신경중재 기기 시장 규모는 어떻게 예측되나요?
  • 신경중재 기기 시장의 주요 성장 요인은 무엇인가요?
  • 신경중재 기기 시장에서 저침습 수술의 수요가 증가하는 이유는 무엇인가요?
  • 고령화 사회가 신경중재 기기 시장에 미치는 영향은 무엇인가요?
  • 신경중재 기기 시장에서 동맥 정맥 기형(AVM)의 중요성은 무엇인가요?
  • 신경중재 기기 시장의 주요 기업은 어디인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 신경중재 기기 시장의 변수, 동향, 범위

  • 시장 계통 전망
    • 부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 시장 기회 분석
    • 시장 과제 분석
  • 신경중재 기기 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석

제4장 신경중재 기기 시장 : 제품별 추정 및 동향 분석

  • 부문 대시보드
  • 신경중재 기기 시장 : 제품별 변동 분석과 시장 점유율, 2024년 및 2030년
  • 진단 기기
  • 치료 기기

제5장 신경중재 기기 시장 : 적응증별 추정 및 동향 분석

  • 부문 대시보드
  • 신경중재 기기 시장 : 적응증별 변동 분석과 시장 점유율, 2024년 및 2030년
  • 급성 허혈성 뇌졸중(AIS)
  • 두개내 동맥류
  • 뇌동맥 협착증
  • 동정맥 기형(AVM)
  • 척추 혈관 기형

제6장 신경중재 기기 시장 : 최종 용도별 추정 및 동향 분석

  • 부문 대시보드
  • 신경중재 기기 시장 : 최종 용도별 변동 분석과 시장 점유율, 2024년 및 2030년
  • 병원
  • 전문 클리닉
  • 외래수술센터(ASC)
  • 기타

제7장 신경중재 기기 시장 : 지역별 추정 및 동향 분석

  • 지역 전망
  • 신경중재 기기 시장 : 지역별 변동 분석과 시장 점유율, 2024년 및 2030년
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제8장 경쟁 구도

  • 시장 진출기업의 분류
  • 주요 기업 프로파일
    • Terumo Neuro
    • NeuroSafe Medical Co., Ltd
    • ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
    • Brain Navi Biotechnology Co., Ltd.
    • Medtronic
    • Stryker
    • CERENOVUS(Johnson & Johnson)
    • Integra LifeSciences Corporation
    • Penumbra Inc
    • Balt SAS
    • B. Braun SE
    • Phenox GmbH
    • Shanghai MicroPort Medical(Group) Co. Ltd.
    • Boston Scientific Corporation
    • Meril
    • Gem srl
    • Sirtex(BlackSwan Vascular, Inc.)
    • INVAMED
    • Merit Medical Systems
    • Abbott
    • Acandis GmbH
    • Cook Medical
    • Imperative Care, Inc.
    • Rapid Medical
    • Koninklijke Philips NV
    • KANEKA CORPORATION
  • 히트맵 분석/기업시장 포지셔닝 분석
  • 기업의 시장 점유율 분석, 2024년
JHS

Neurointerventional Devices Market Summary

The global neurointerventional devices market size was estimated at USD 2.95 billion in 2024 and is projected to reach USD 4.96 billion by 2033, growing at a CAGR of 5.9% from 2025 to 2033. The market is primarily driven by the rising prevalence of stroke, brain aneurysms, vascular malformations and other neurovascular disorders, coupled with the rapidly growing aging population prone to such conditions.

Increasing demand for minimally invasive procedures, which offer faster recovery and fewer complications than open surgery, further accelerates market growth. The rising incidence of neurological disorders such as stroke, aneurysms, and other neurovascular conditions is a key driver of the neurointerventional devices market, as it increases the demand for effective, minimally invasive treatments that can reduce disability, improve survival rates, and enhance patient outcomes. According to the World Federation of Neurology (WFN), neurological disease prevalence varies across age groups, including preterm, neonatal, childhood, adolescent, adult, and older adults who often experience age-related multimorbidity and frailty. The 2024 Global Burden of Disease study estimated that 43% of the world's population is affected by a neurological disorder, underscoring the significant global demand for neurointerventional devices and treatments.

Technological advancements, including next-generation stent retrievers, flow diverters, and advanced imaging solutions, enhance treatment outcomes. Favorable regulatory approvals, improved reimbursement policies, and expanding healthcare infrastructure in emerging markets are supporting wider adoption of neurointerventional devices. For instance, in April 2024, Neurology journals have highlighted projections estimating that the number of brain disorder cases could reach 4.9 billion globally by 2050, marking a 22% increase compared to 2021. The all-age Disability-Adjusted Life Years (DALYs) rate of brain disorders is also expected to rise significantly by 10% globally, from 5,139 DALYs per 100,000 in 2021 to 5,666 DALYs per 100,000 in 2050. Headaches, Alzheimer's disease, depressive and anxiety disorders, and strokes are identified as the primary contributors to this anticipated surge in prevalence and disease burden.

The rising incidence of stroke, particularly ischemic stroke is propelling the neurointerventional devices market by increasing the demand for efficient and minimally invasive clot removal procedures. For instance, in 2024, CDC data highlighted, as presented in the table below, that over 795,000 people in the U.S. suffer a stroke each year, emphasizing the growing need for advanced neurointerventional treatment options.[ According to the WHO, the global incidence of stroke is estimated to be approximately 15 million people annually, with ischemic stroke representing about 87% of all stroke cases.

According to the World Stroke Organization 2022, the table below shows the incidence and prevalence of ischemic stroke.

According to the Journal of Experimental Stroke & Translational Medicine, Hemorrhagic stroke accounts for approximately 10-15% of cases and results from the rupture of a blood vessel, causing bleeding within the brain tissue (intracerebral hemorrhage) or into the space surrounding the brain (subarachnoid hemorrhage).

Arteriovenous malformations (AVMs) are a significant factor driving the growth of the neurointerventional devices market, as these complex vascular abnormalities require precise and minimally invasive treatment approaches. The increasing detection of AVMs through advanced imaging techniques and the growing preference for endovascular procedures over open surgery fuel the demand for specialized neurointerventional devices such as embolization systems, catheters, and coils. Rising awareness among healthcare professionals about early intervention to prevent hemorrhagic complications further accelerates the adoption of advanced neurointerventional solutions for AVM management. According to a research article published by the National Center for Biotechnology Information, arteriovenous malformations (AVMs) are often asymptomatic in about 15% of cases until a clinical event occurs. Between 41% and 79% of AVMs are present with intracranial hemorrhage. They are the second most common cause of intracranial bleeding after cerebral aneurysms, accounting for approximately 10% of all subarachnoid hemorrhages.

The growing aging population drives the neurointerventional devices market, as older adults are more prone to neurovascular conditions such as stroke, aneurysms, and age-related cerebrovascular diseases. This demographic trend increases the demand for minimally invasive interventions and advanced neurovascular devices. For instance, in June 2024, the Brain Aneurysm Foundation reported that an estimated 6.8 million people in the United States, about 1 in 50, have an unruptured brain aneurysm, with an annual rupture rate of 8-10 per 100,000 people. Each year, roughly 30,000 Americans experience a brain aneurysm rupture, which occurs on average every 18 minutes. Globally, brain aneurysms cause nearly 500,000 deaths annually, with half of the victims under 50. While most aneurysms develop after age 40 and are most common between ages 35 to 60, they can also occur in children. Women are more likely than men to have a brain aneurysm (3:2 ratio), and women over 55 faces approximately 1.5 times higher risk of rupture than men.

Global Neurointerventional Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neurointerventional devices market report based on product, indication, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostic Devices
    • Catheters
    • Distal Access Catheters
    • Microcatheters
    • Others
    • Guidewires
    • Imaging Systems
  • Therapeutic Devices
    • Embolic Materials
    • Embolic Coils
    • Embolic Agents
    • Neurovascular Stents
    • Self-Expanding Stents
    • Balloon-Expandable Stents
    • Flow Diverter Stents
    • Coil-Assist Stents
    • Neurothrombectomy Devices
    • Intrasaccular Devices
    • Embolic Protection Devices
    • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Acute Ischemic Stroke (AIS)
  • Intracranial Aneurysm
  • Cerebral Arterial Stenosis
  • Arteriovenous Malformation (AVM)
  • Spinal Vascular Malformations
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Product
    • 1.2.3. Indication
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Neurointerventional Devices Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Neurovascular Disorders
      • 3.2.1.2. Growing Preference for Minimally Invasive Procedures
      • 3.2.1.3. Regulatory Approvals and Reimbursement Policies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High procedural and device costs
    • 3.2.3. Market Opportunities Analysis
      • 3.2.3.1. Rising prevalence of stroke and cerebrovascular disorders
      • 3.2.3.2. Integration of AI and robotics
    • 3.2.4. Market Challenges Analysis
      • 3.2.4.1. Complexity of neurovascular anatomy
      • 3.2.4.2. Device-related risks and failures
  • 3.3. Neurointerventional Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape

Chapter 4. Neurointerventional Devices Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Neurointerventional Devices Market: Product Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Diagnostic Devices
    • 4.3.1. Diagnostic Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.1.1. Catheters
        • 4.3.1.1.1. Catheters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.3.1.1.1.1. Distal Access Catheters
            • 4.3.1.1.1.1.1. Distal Access Catheters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.3.1.1.1.2. Microcatheters
            • 4.3.1.1.1.1.2. Microcatheters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.3.1.1.1.3. Others
            • 4.3.1.1.1.1.3. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.1.2. Guidewires
        • 4.3.1.1.2. Guidewires Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.1.3. Imaging Systems
        • 4.3.1.3.1. Imaging Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Therapeutic Devices
    • 4.4.1. Therapeutic Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1. Embolic Materials
        • 4.4.1.1.1. Embolic Materials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.1.1.1.1. Embolic Coils
            • 4.4.1.1.1.1.1. Embolic Coils Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.1.1.1.2. Embolic Agents
            • 4.2.1.1.1.2.1. Embolic Agents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.2. Neurovascular Stents
        • 4.4.1.2.1. Neurovascular Stents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.1.2.1.1. Self-Expanding Stents
            • 4.4.1.2.1.1.1. Self-Expanding Stents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.1.2.1.2. Balloon-Expandable Stents
            • 4.4.1.2.1.2.1. Balloon-Expandable Stents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.1.2.1.3. Flow Diverter Stents
            • 4.4.1.2.1.3.1. Flow Diverter Stents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.1.2.1.4. Coil-Assist Stents
            • 4.4.1.2.1.4.1. Coil-Assist Stents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.3. Neurothrombectomy Devices
        • 4.4.1.3.1. Neurothrombectomy Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.4. Intrasaccular Devices
        • 4.4.1.4.1. Intrasaccular Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.5. Embolic Protection Devices
        • 4.4.1.5.1. Embolic Protection Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.6. Others
        • 4.4.1.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Neurointerventional Devices Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Neurointerventional Devices Market: Indication Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Acute Ischemic Stroke (AIS)
    • 5.3.1. Acute Ischemic Stroke (AIS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Intracranial Aneurysm
    • 5.4.1. Intracranial Aneurysm Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cerebral Arterial Stenosis
    • 5.5.1. Cerebral Arterial Stenosis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Arteriovenous Malformation (AVM)
    • 5.6.1. Arteriovenous Malformation (AVM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Spinal Vascular Malformations
    • 5.7.1. Spinal Vascular Malformations Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Neurointerventional Devices Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Neurointerventional Devices Market: End Use Movement Analysis & Market Share, 2024 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Specialty Clinics
    • 6.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Ambulatory Surgery Centers
    • 6.5.1. Ambulatory Surgery Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Neurointerventional Devices Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Neurointerventional Devices Market: Regional Movement Analysis & Market Share, 2024 & 2030
  • 7.3. North America
    • 7.3.1. North America Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Scenario
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. U.S. Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Scenario
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Canada Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Scenario
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Mexico Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. UK Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Germany Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Scenario
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. France Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Scenario
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Italy Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Scenario
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Spain Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Scenario
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Denmark Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Scenario
      • 7.4.8.4. Reimbursement Scenario
      • 7.4.8.5. Sweden Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Scenario
      • 7.4.9.4. Reimbursement Scenario
      • 7.4.9.5. Norway Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Japan Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. China Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. India Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Reimbursement Scenario
      • 7.5.5.5. South Korea Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Reimbursement Scenario
      • 7.5.6.5. Australia Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Reimbursement Scenario
      • 7.5.7.5. Thailand Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Brazil Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Argentina Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Middle East & Africa
    • 7.7.1. Middle East & Africa Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Reimbursement Scenario
      • 7.7.2.5. South Africa Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Reimbursement Scenario
      • 7.7.3.5. Saudi Arabia Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Reimbursement Scenario
      • 7.7.4.5. UAE Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Scenario
      • 7.7.5.4. Reimbursement Scenario
      • 7.7.5.5. Kuwait Neurointerventional Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. Terumo Neuro
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Technology Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. NeuroSafe Medical Co., Ltd
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Technology Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Technology Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Brain Navi Biotechnology Co., Ltd.
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Technology Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Medtronic
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Technology Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Stryker
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Technology Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. CERENOVUS (Johnson & Johnson)
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Technology Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Integra LifeSciences Corporation
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Technology Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. Penumbra Inc
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Technology Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Balt SAS
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Technology Benchmarking
      • 8.2.10.4. Strategic Initiatives
    • 8.2.11. B. Braun SE
      • 8.2.11.1. Company Overview
      • 8.2.11.2. Financial Performance
      • 8.2.11.3. Technology Benchmarking
      • 8.2.11.4. Strategic Initiatives
    • 8.2.12. Phenox GmbH
      • 8.2.12.1. Company Overview
      • 8.2.12.2. Financial Performance
      • 8.2.12.3. Technology Benchmarking
      • 8.2.12.4. Strategic Initiatives
    • 8.2.13. Shanghai MicroPort Medical (Group) Co. Ltd.
      • 8.2.13.1. Company Overview
      • 8.2.13.2. Financial Performance
      • 8.2.13.3. Technology Benchmarking
      • 8.2.13.4. Strategic Initiatives
    • 8.2.14. Boston Scientific Corporation
      • 8.2.14.1. Company Overview
      • 8.2.14.2. Financial Performance
      • 8.2.14.3. Technology Benchmarking
      • 8.2.14.4. Strategic Initiatives
    • 8.2.15. Meril
      • 8.2.15.1. Company Overview
      • 8.2.15.2. Financial Performance
      • 8.2.15.3. Technology Benchmarking
      • 8.2.15.4. Strategic Initiatives
    • 8.2.16. Gem srl
      • 8.2.16.1. Company Overview
      • 8.2.16.2. Financial Performance
      • 8.2.16.3. Technology Benchmarking
      • 8.2.16.4. Strategic Initiatives
    • 8.2.17. Sirtex (BlackSwan Vascular, Inc.)
      • 8.2.17.1. Company Overview
      • 8.2.17.2. Financial Performance
      • 8.2.17.3. Technology Benchmarking
      • 8.2.17.4. Strategic Initiatives
    • 8.2.18. INVAMED
      • 8.2.18.1. Company Overview
      • 8.2.18.2. Financial Performance
      • 8.2.18.3. Technology Benchmarking
      • 8.2.18.4. Strategic Initiatives
    • 8.2.19. Merit Medical Systems
      • 8.2.19.1. Company Overview
      • 8.2.19.2. Financial Performance
      • 8.2.19.3. Technology Benchmarking
      • 8.2.19.4. Strategic Initiatives
    • 8.2.20. Abbott
      • 8.2.20.1. Company Overview
      • 8.2.20.2. Financial Performance
      • 8.2.20.3. Technology Benchmarking
      • 8.2.20.4. Strategic Initiatives
    • 8.2.21. Acandis GmbH
      • 8.2.21.1. Company Overview
      • 8.2.21.2. Financial Performance
      • 8.2.21.3. Technology Benchmarking
      • 8.2.21.4. Strategic Initiatives
    • 8.2.22. Cook Medical
      • 8.2.22.1. Company Overview
      • 8.2.22.2. Financial Performance
      • 8.2.22.3. Technology Benchmarking
      • 8.2.22.4. Strategic Initiatives
    • 8.2.23. Imperative Care, Inc.
      • 8.2.23.1. Company Overview
      • 8.2.23.2. Financial Performance
      • 8.2.23.3. Technology Benchmarking
      • 8.2.23.4. Strategic Initiatives
    • 8.2.24. Rapid Medical
      • 8.2.24.1. Company Overview
      • 8.2.24.2. Financial Performance
      • 8.2.24.3. Technology Benchmarking
      • 8.2.24.4. Strategic Initiatives
    • 8.2.25. Koninklijke Philips N.V.
      • 8.2.25.1. Company Overview
      • 8.2.25.2. Financial Performance
      • 8.2.25.3. Technology Benchmarking
      • 8.2.25.4. Strategic Initiatives
    • 8.2.26. KANEKA CORPORATION
      • 8.2.26.1. Company Overview
      • 8.2.26.2. Financial Performance
      • 8.2.26.3. Technology Benchmarking
      • 8.2.26.4. Strategic Initiatives
  • 8.3. Heat Map Analysis/ Company Market Position Analysis
  • 8.4. Company Market Share Analysis, 2024
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제